iBio to Present at Wells Fargo Annual Healthcare Conference

SAN DIEGO, Sept. 01, 2026 /CourierPR/ -- iBio, a clinical-stage biotechnology company specializing in long-acting antibody therapeutics for obesity and cardiometabolic diseases, will participate in the 2026 Wells Fargo Annual Healthcare Conference. The event, scheduled for September 8-10, 2026, in Boston, will feature key discussions on the latest advancements in healthcare.

On Tuesday, September 8, at 4:30 p.m. Eastern Time, iBio’s Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will lead a fireside chat. The session will provide insights into the company's ongoing research and development efforts, including its pipeline of long-acting antibody therapeutics.

Martin Brenner, speaking on behalf of iBio, commented, "We are excited to present at the Wells Fargo Annual Healthcare Conference and share our progress in developing innovative long-acting antibody therapeutics. This platform provides us with a valuable opportunity to engage with key stakeholders and discuss the potential impact of our research."

The company’s mission is to transform drug discovery and accelerate the development of precision medicine through advanced antibody engineering and AI-driven discovery. iBio's pipeline includes therapies for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other challenging conditions.